← Back to Search

Radiation Therapy

Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

Phase 1
Waitlist Available
Led By Ken Nedd, M.D.
Research Sponsored by GAAD Medical Research Institute Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* People with HD
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances. This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Eligible Conditions
  • Huntington's Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Find a Location

Who is running the clinical trial?

GAAD Medical Research Institute Inc.Lead Sponsor
21 Previous Clinical Trials
90 Total Patients Enrolled
Ken Nedd, M.D.Principal InvestigatorGAAD Medical Research Institute Inc.
19 Previous Clinical Trials
88 Total Patients Enrolled
~0 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top